The need for new solutions treating respiratory tract infections is significant, this is a market which with conservative estimates for the EU and the US is approximately 12 billion USD. The number can probably be doubled looking in a global perspective
CEO, Geir Almås
This technology is unique, it is simple, and exceptionally efficient. I am convinced that we are facing a breakthrough in the treatment of difficult infections.
My team and I believe that we are facing a breakthrough in the treatment of difficult infections, both viral and bacterial. We have tested SoftOx solutions in the respiratory tract and we see that this can be an important treatment principle that can help fight the ongoing pandemic and future epidemics and pandemics
It is my belief that SIS could and will contribute to limiting child death due to respiratory infections. SIS will put an end to COVID-19 domination as well as the regular influenza and other known airway infections. Also, SIS will help prepare us for the next pandemic by giving us a highly effective weapon with wide applications making a crucial difference as we face disease X. I foresee we are stepping into a new era due to SIS; a+n era with less use of antibiotics for bacterial respiratory infections as well as a world which does not have to close down due to a simple virus. SIS offers a harmless, simple way of ending or at least mitigating known and even unknown respiratory infections.
Thomas Bjarnsholt, DMSc and Professor at
Copenhagen University and University Hospital
Jeg har jobbet mye med motmidler mot kjemiske stridsmidler, og SoftOx’ inhalatorløsning har et potensiale vi ikke har sett før
-Øyvind Voie, Forsvarets Forskningsinstitutt
Noen utvalgte sitater mens vi tuktes i jammerdalen.
